H.C. Wainwright reiterates Oculis stock rating on trial completion By Investing.com

AMZN’s incremental capital commitment should be read less as a near-term P&L event and more as a strategic moat expansion: it likely deepens model access, preferential compute allocation, and customer stickiness across AWS rather than just financing a partner. The second-order winner is the cloud stack around Anthropic — if training and inference workloads scale, AWS utilization and AI attach rates can compound even if headline economics are opaque today. The market may underappreciate that this is also a defensive move against competitors that are using model partnerships to pull enterprise workloads away from AWS.

For OCS, the setup is asymmetric but timing matters. The stock is now trading as a binary readout on a multi-year asset, yet the path to value is still punctuated by dilution risk and a long data gap, which can cap upside until topline results are closer. The real question is not whether the asset has optionality, but whether the market is overpaying for probability-weighted success before a single pivotal data point is in hand.

The contrarian view is that analyst enthusiasm may be conflating addressable market size with capture probability. Ophthalmology launches often disappoint on real-world adherence and commercial uptake, especially when dosing burden is high and payer friction is non-trivial. If the data are merely good rather than clearly differentiated, the current rerating can unwind quickly because the stock has already absorbed a meaningful amount of success premium ahead of the catalyst.

Near term, AMZN should trade on narrative reinforcement and cloud multiple support, while OCS remains a longer-dated catalyst trade with a financing overhang. The key risk for AMZN is that investors treat the investment as earnings-accretive rather than strategic, leading to disappointment in the absence of a near-term revenue inflection. For OCS, the main reversal triggers are additional equity issuance, trial noise, or any signal that the drug’s efficacy/usage profile is not compelling enough to change prescribing behavior at scale.